These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36413888)

  • 1. Realgar and arsenene nanomaterials as arsenic-based anticancer agents.
    Hollow SE; Johnstone TC
    Curr Opin Chem Biol; 2023 Feb; 72():102229. PubMed ID: 36413888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The medicinal use of realgar (As₄S₄) and its recent development as an anticancer agent.
    Wu J; Shao Y; Liu J; Chen G; Ho PC
    J Ethnopharmacol; 2011 Jun; 135(3):595-602. PubMed ID: 21497649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro.
    Pastorek M; Gronesova P; Cholujova D; Hunakova L; Bujnakova Z; Balaz P; Duraj J; Lee TC; Sedlak J
    Neoplasma; 2014; 61(6):700-9. PubMed ID: 25150315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
    Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
    Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
    Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
    Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Liao LH; Chen YQ; Huang DP; Wang LN; Ye ZL; Yang LH; Mai HR; Li Y; Liang C; Luo JS; Wang LN; Luo XQ; Tang YL; Zhang XL; Huang LB
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):45-52. PubMed ID: 35760920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
    Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
    AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
    Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
    Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite.
    Liu J; Lu Y; Wu Q; Goyer RA; Waalkes MP
    J Pharmacol Exp Ther; 2008 Aug; 326(2):363-8. PubMed ID: 18463319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preliminary study of Realgar and arsenic trioxide on gut microbiota of mice].
    Sun YT; Xu HH; Nie Y; Wang YG; Ma ZC; Zhou W; Tan HL; Gao Y
    Zhongguo Zhong Yao Za Zhi; 2020 Jan; 45(1):142-148. PubMed ID: 32237423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
    Wang QQ; Hua HY; Naranmandura H; Zhu HH
    Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Chou WC; Dang CV
    Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
    Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
    Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
    Fu X; Li YS; Zhao J; Yu LL; Luo RG; Liang QR; Tang Q
    Mini Rev Med Chem; 2020; 20(3):239-251. PubMed ID: 31760930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
    Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond.
    Maimaitiyiming Y; Wang QQ; Hsu CH; Naranmandura H
    Toxicol Appl Pharmacol; 2020 Nov; 406():115212. PubMed ID: 32882258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding the use of arsenic trioxide: leukemias and beyond.
    Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide in pediatric cancer - a case series and review of literature.
    Abele M; Müller SL; Schleicher S; Hartmann U; Döring M; Queudeville M; Lang P; Handgretinger R; Ebinger M
    Pediatr Hematol Oncol; 2021 Aug; 38(5):471-485. PubMed ID: 33635158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
    J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
    Gao C; Hu S; Guo M; Hai X; Zhou J
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.